Repligen (RGEN) News Today $127.59 +1.40 (+1.11%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGEN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Polar Asset Management Partners Inc. Buys 3,000 Shares of Repligen Co. (NASDAQ:RGEN)Polar Asset Management Partners Inc. increased its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 76.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,900 shares of the biotechnology company's stock after purchasingMay 20 at 5:29 AM | marketbeat.comGotham Asset Management LLC Has $965,000 Stake in Repligen Co. (NASDAQ:RGEN)Gotham Asset Management LLC decreased its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 78.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,702 shares of the biotechnoloMay 20 at 4:29 AM | marketbeat.comRepligen Co. (NASDAQ:RGEN) Receives $173.25 Average Price Target from AnalystsMay 20 at 2:23 AM | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Given Average Recommendation of "Moderate Buy" by AnalystsRepligen Co. (NASDAQ:RGEN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen ratings firms that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendatioMay 19 at 2:11 AM | marketbeat.comBank of America Corp DE Trims Holdings in Repligen Co. (NASDAQ:RGEN)Bank of America Corp DE trimmed its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 36.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 277,947 shares of the biotechnology company's stock after selling 158,404 shares during the period. Bank ofMay 18 at 3:42 AM | marketbeat.comCritical Survey: Repligen (NASDAQ:RGEN) versus Maze Therapeutics (NASDAQ:MAZE)May 18 at 2:11 AM | americanbankingnews.comPoint72 Asset Management L.P. Has $132.23 Million Stake in Repligen Co. (NASDAQ:RGEN)Point72 Asset Management L.P. lifted its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 183.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 918,623 shares of the biotechnology company's stock after acquiriMay 17 at 7:44 AM | marketbeat.comInsider Sell: Anthony Hunt Sells 26,447 Shares of Repligen Corp (RGEN)May 17 at 4:13 AM | gurufocus.comRepligen Holds Annual Shareholders Meeting, Key Decisions MadeMay 15, 2025 | tipranks.comIntegral Health Asset Management LLC Purchases New Holdings in Repligen Co. (NASDAQ:RGEN)Integral Health Asset Management LLC acquired a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 40,000 shares of the biotechnology company's stock, valued at appMay 14, 2025 | marketbeat.comAlgert Global LLC Invests $844,000 in Repligen Co. (NASDAQ:RGEN)Algert Global LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 5,865 shares of the biotechnology company's stock, valued at approximaMay 13, 2025 | marketbeat.comRepligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To KnowMay 12, 2025 | msn.comRepligen (NASDAQ:RGEN) Stock Unloaded Rep. Jefferson ShreveRepresentative Jefferson Shreve (R-Indiana) recently sold shares of Repligen Co. (NASDAQ:RGEN). In a filing disclosed on May 08th, the Representative disclosed that they had sold between $15,001 and $50,000 in Repligen stock on April 7th. The trade occurred in the Representative's "CRT - STANDARD UMay 12, 2025 | marketbeat.comGranahan Investment Management LLC Acquires 19,160 Shares of Repligen Co. (NASDAQ:RGEN)Granahan Investment Management LLC increased its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 21.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,415 shares of the biotechMay 12, 2025 | marketbeat.comFred Alger Management LLC Sells 39,047 Shares of Repligen Co. (NASDAQ:RGEN)Fred Alger Management LLC reduced its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 9.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 359,507 shares of the biotechnology company's stock after sellMay 10, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 25,168 Shares of Repligen Co. (NASDAQ:RGEN)Ameriprise Financial Inc. lessened its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 929,090 shares of the biotechnology company's stock after selling 25,168 shares dMay 10, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Upgraded to "Hold" at StockNews.comStockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research report on Thursday.May 10, 2025 | marketbeat.comBridgefront Capital LLC Makes New Investment in Repligen Co. (NASDAQ:RGEN)Bridgefront Capital LLC acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 3,904 shares of the biotechnology company's stock, valued at approximately $562,000. A nuMay 8, 2025 | marketbeat.comBayesian Capital Management LP Makes New $947,000 Investment in Repligen Co. (NASDAQ:RGEN)Bayesian Capital Management LP purchased a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,578 shares of the biotechnology company's stock, valMay 8, 2025 | marketbeat.comNorthern Trust Corp Has $71.07 Million Position in Repligen Co. (NASDAQ:RGEN)Northern Trust Corp increased its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 26.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 493,713 shares of the biotechnMay 8, 2025 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Sold by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 3.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,199 shares of the biotechnology company's stocMay 8, 2025 | marketbeat.comRepligen's (RGEN) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a report on Monday.May 7, 2025 | marketbeat.comRepligen Corporation to Present at Upcoming May Investor ConferencesMay 7, 2025 | globenewswire.comBaird Financial Group Inc. Cuts Stake in Repligen Co. (NASDAQ:RGEN)Baird Financial Group Inc. cut its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 7.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 354,237 shares of the biotechnology companMay 7, 2025 | marketbeat.comBamco Inc. NY Lowers Position in Repligen Co. (NASDAQ:RGEN)Bamco Inc. NY reduced its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 4.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 160,227 shares of the biotechnology company's stock after selMay 7, 2025 | marketbeat.comAlyeska Investment Group L.P. Makes New Investment in Repligen Co. (NASDAQ:RGEN)Alyeska Investment Group L.P. bought a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 371,180 shares of the biotechnology company's stock, valuMay 6, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Takes Position in Repligen Co. (NASDAQ:RGEN)Susquehanna Fundamental Investments LLC bought a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,000 shares of the biotechnology company'May 6, 2025 | marketbeat.comRepligen’s Strategic Growth and Resilience Drive Buy Rating with $180 Price TargetMay 5, 2025 | tipranks.comFY2025 EPS Estimates for Repligen Boosted by William BlairRepligen Co. (NASDAQ:RGEN - Free Report) - Analysts at William Blair increased their FY2025 earnings per share estimates for Repligen in a report issued on Wednesday, April 30th. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings of $1.68 per share forMay 4, 2025 | marketbeat.comQ2 Earnings Estimate for Repligen Issued By Leerink PartnrsRepligen Co. (NASDAQ:RGEN - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q2 2025 earnings per share (EPS) estimates for shares of Repligen in a research note issued to investors on Tuesday, April 29th. Leerink Partnrs analyst P. Souda now anticipates that the biotechMay 4, 2025 | marketbeat.comStifel Nicolaus Reaffirms Their Buy Rating on Repligen (RGEN)May 3, 2025 | theglobeandmail.comWilliam Blair Brokers Lower Earnings Estimates for RepligenRepligen Co. (NASDAQ:RGEN - Free Report) - William Blair decreased their Q2 2025 earnings per share (EPS) estimates for shares of Repligen in a research note issued to investors on Wednesday, April 30th. William Blair analyst M. Larew now forecasts that the biotechnology company will earn $0.41 pMay 3, 2025 | marketbeat.comRepligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On HealthcareMay 2, 2025 | msn.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), SAGE Therapeutics (SAGE) and Repligen (RGEN)May 2, 2025 | theglobeandmail.comDimensional Fund Advisors LP Raises Holdings in Repligen Co. (NASDAQ:RGEN)Dimensional Fund Advisors LP boosted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 28.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 580,485 shares of the biotechnology company's stock after buying an additMay 2, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Upgraded to "Outperform" at Wolfe ResearchWolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a research note on Tuesday.May 1, 2025 | marketbeat.comJim Cramer on Repligen Corporation (RGEN): ‘I’m Not Quite Ready to Stick My Neck Out on This One’May 1, 2025 | insidermonkey.comRepligen (NASDAQ:RGEN) Releases Earnings Results, Beats Estimates By $0.04 EPSRepligen (NASDAQ:RGEN - Get Free Report) released its earnings results on Tuesday. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.28 earnings per share.May 1, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Shares Gap Down - What's Next?Repligen (NASDAQ:RGEN) Shares Gap Down - What's Next?May 1, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Updates FY 2025 Earnings GuidanceRepligen (NASDAQ:RGEN) updated its FY 2025 earnings guidance. The company provided EPS guidance of 1.630-1.720 for the period, compared to the consensus estimate of 1.710. The company also issued revenue guidance of $695.0 millionillion-$720.0 millionillion, compared to the consensus estimate of $700.8 millionillion.May 1, 2025 | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Q1 2025 Earnings Call TranscriptMay 1, 2025 | msn.com7RGEN : Deep Dive Into Repligen Stock: Analyst Perspectives...May 1, 2025 | benzinga.comRGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff UncertaintyMay 1, 2025 | msn.comRepligen (RGEN) Price Target Adjusted by RBC Capital Amid Market Trends | RGEN Stock NewsApril 30, 2025 | gurufocus.comRepligen (RGEN) Price Target Adjusted by RBC Capital Amid Market Trends | RGEN Stock NewsApril 30, 2025 | gurufocus.comFirst Light Asset Management LLC Trims Stock Position in Repligen Co. (NASDAQ:RGEN)First Light Asset Management LLC decreased its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 50.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 82,455 shares of the biotechnology company's stock after selling 83,418April 30, 2025 | marketbeat.comRepligen’s Fair Valuation and Cautious Growth Outlook Lead to Hold RatingApril 30, 2025 | tipranks.comRepligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds ExpectationsApril 30, 2025 | msn.comRepligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...April 30, 2025 | gurufocus.comRepligen Corporation (RGEN) Q1 2025 Earnings Call TranscriptApril 29, 2025 | seekingalpha.com Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Media Mentions By Week RGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGEN News Sentiment▼1.280.65▲Average Medical News Sentiment RGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGEN Articles This Week▼109▲RGEN Articles Average Week Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Biogen News United Therapeutics News Incyte News Exelixis News Neurocrine Biosciences News BioMarin Pharmaceutical News Exact Sciences News Halozyme Therapeutics News Madrigal Pharmaceuticals News Ionis Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGEN) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Buy” Alert! This stock could soar by July 31stTHREE companies in particular are leading the charge during this exciting time. Here’s why I’m so excited a...Traders Agency | SponsoredAI Firm Enters America's Largest Medicaid MarketNew York's $95B system just approved a new AI healthcare platform. Here's what to know. A major shift in U....i2i Marketing Group, LLC | SponsoredTrump’s treachery A shocking bill has been put before the House of Representatives… Representative Brandon Gill wants Preside...Porter & Company | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RGEN Stock Free RGEN Stock Alerts